# (Translation)



# Minutes of the 2023 Annual General Meeting of Shareholders (Reschedule)

of

E for L Aim Public Company Limited

# Date, Time and Venue of the Meeting

The Meeting was arranged on Monday, May 8, 2023, at 2.00 p.m., though the electronic media under the Emergency Decree on Teleconferences through Electronic Devices B.E. 2563 (2020) via Application IR PLUS AGM collecting the information of all attendees for supporting evidence i.e., username, date and time to attend and leave the meeting together with photo and voice memo and result of their votes. The meeting shall be conducted by regulation and law of related regulation offices; Ministry of Commerce, The Stock Exchange of Thailand, The Securities and Exchange Commission and the information security related to under the Emergency Decree on Teleconferences through Electronic Devices B.E. 2563 (2020) of which the meeting has broadcast via an electronic means from the meeting room 6<sup>th</sup> floor, the Building No. 160, Ngamwongwan Road, Bang Khen, Mueang Nonthaburi, Nonthaburi.

# Directors and Executives Attending the Meeting

1. Mr. Preecha Nuntnarumit	Director, Chairman of Executive Director, Chief Executive
	Officer and Managing Director
2. Mr. Rujapong Prabhasanobol	Independent Director and Chairman of the Audit Committee
3. Mr. Jitkasem Sangsingkeo	Independent Director and Member of the Audit Committee
4. Mr. Pipat Yingseree	Independent Director and Member of the Audit Committee
5. Mr. Jackrit Lohajaroensub	Director and Executive Director
6. Ms. Watacharaporn Suwinchai	Director
7. Mr. Apirak Kanchanakongkha	Acting Chief Finance Officer

Equal to 85.71% of the total number of directors (Seven persons)

# Director not Attending the Meeting

Mr. Tachaphol Kanjanakul	Chairman of the Board
Others Attending the Meeting	
Mr. Somkid Taitragul	Certified Public Accountant from Grant Thornton Company
	Limited

# Before the Meeting Started:

Miss Chonticha Pumpruek delivered a welcome speech to the shareholders at the 2023 Annual General Meeting of Shareholders of E for L Aim Public Company Limited through electronic media via the IR PLUS AGM application. She clarified the information to the meeting as follows:

For the convenience and efficiency, the Meeting shall consider the matters in order of the agenda stated in the Invitation Letter. The information in each agenda shall be presented and the shareholders are given the opportunity to firstly interrogate prior to vote on such agenda. The vote casting and counting procedures are explained to shareholders, as follows:

- 1. Shareholders may cast their votes of approval, disapproval, or abstention via the Application IR PLUS AGM by pressing the button to agree, disagree and abstain and press confirm.
- 2. When the Chairman of the Meeting notified shareholders to pass the resolution in each session, the system will allow to cast their votes in the specific period in each session. Shareholders may cast their votes of approval, disapproval or abstention and press confirm.
- 3. The Company would count only votes of disapproval and abstention of shareholders, then, the number of such votes of disapproval and abstention shall be deducted from the total number of votes of shareholders. Then, the remaining votes shall be regarded as votes of approval in such sessions.
- 4. For shareholders do not cast their votes within the specific period for voting, the Company will deem as approval due to the online electronic vote application resulting in no voided ballot.
- 5. Shareholders are enabled to change their votes until closing the voting period in the system for counting the total votes. If the time out, shareholders are unable to change the votes on such agenda.
- 6. For the shareholder who authorizes other person to attend the meeting in lieu of him/her and votes in the Proxy, the Company shall record such vote as specified by the shareholder in Proxy.
- 7. Method of counting votes: 1 share is equal to 1 vote.
- 8. This meeting has set out each agenda to propose for the shareholder to approve with various resolution as follows:

- For agenda 1, 3, 4, 5 and 7: the resolutions must be passed with the majority votes of shareholders attending the Meeting and having the voting rights.

- For agenda 6, the resolutions must be passed with at least 2/3 of the total votes of shareholders attending the Meeting and having the voting rights.

- For agenda 2 of the Meeting was fixed for notification and requiring no passing of resolutions.

In case shareholder or proxy wishing to make inquiries or to express opinions in such agenda, he/she can click questions and type his/her inquires or opinion via Application IR Plus AGM all the time until closing the session.

- 9. In case any shareholder wishing to make inquiries or to express opinions not related to such agenda, he/she may express opinions in agenda 8 "To consider and approve other issues".
- 10. In case, shareholders additionally attended during the meeting, shareholders or proxies may exercise their voting rights only in such agenda that they attended, and resolutions thereof have not yet been passed. The Company shall report the number of shareholders and voting shares to the Meeting.

There were shareholders and Proxies attending the meeting as follows:

Shareholders	2 Persons	Number of Shares:	62,037,185 shares
Proxies	45 Persons	Number of Shares:	849,035,373 shares
Shareholders Online	11 Persons	Number of Shares:	51,723,994 shares
Proxy Online	1 Person	Number of Shares:	100 shares

A total of 59 shareholders representing 962,796,652 shares, equivalent to 24.0828% of the total paidup capital (3,997,864,980 shares), attended the meeting. However, this does not meet the quorum requirement stated in paragraph one, Article 38 of the Company's Articles of Association.

This meeting is a rescheduled one after the previous shareholders' meeting on April 18, 2023, which was unable to proceed due to an insufficient quorum. The Board of Directors resolved to convene a new meeting of shareholders today. According to Article 38 of the Company's Articles of Association, a quorum is not necessary for the second meeting.

At this time, I would like to invite Mr. Preecha Nuntnaumit, the chairman of the meeting, to commence the session.

# The Meeting Started at 2.15 p.m.:

Mr. Preecha Nuntnarumit, the Chairman of the Meeting, addressed to start the Meeting as per the following agenda:

# Agenda 1To consider and certify the Minutes of the 2022 Annual General Meeting of Shareholders.The Chairman of the Meeting: proposed the matter to the Meeting to consider and adopt the<br/>Minutes of the 2022 Annual General Meeting of Shareholders hold on April 8, 2022. The Company<br/>has submitted copy of the minutes of the meeting to the Stock Exchange of Thailand according<br/>to Public Law. The minutes were also posted on the Company website and delivered to all<br/>shareholders, together with the Invitation for Shareholders' Meeting.

The Chairman of the Meeting: provided all shareholders with an opportunity to make inquiries. It was evident that there were no objections or requests for amendments to the Minutes from any shareholders. The Chairman of the Meeting proposed that the meeting consider adopting the Minutes of the 2022 Annual General Meeting of Shareholders. **Miss Chonticha Pumpruek** (Master of Ceremony) reported that, in this Agenda, the number of shareholders attending the Meeting increased by 2 shareholders, totaling 1,105,000 shares. Therefore, there were 61 shareholders attending the meeting with total 963,901,652 shares.

**Resolution** The Meeting passed its resolution to adopt the Minutes of the 2022 Annual General Meeting of Shareholders, as proposed by the Chairman of the Meeting with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
Shares	953,901,652	-	10,000,000	-
Percentage	100.0000	-	-	-

# Agenda 2To acknowledge the Annual Registration Statement / Annual Report for the year ended 31December 2022 (Form 56-1 One Report) and the Company's 2022 operating results.

The Chairman of the Meeting: Assigned Miss Chonticha Pumpruek to present the details to the meeting.

**Miss Chonticha Pumpruek**: The Company prepared the Annual Registration Statement / Annual report as at 31 December 2022 (56-1 One Report) and the operating performance for the year 2022 of which the board of directors considered it to be complete and correct. The report was presented in the form of a QR Code shown on the registered documents and has already been submitted to the shareholders together with the notification letter. I would like to present the Company's performance for the fiscal year 2022 by summarising the key information to the meeting as follows:

The overall revenue in 2022 was Baht 1,511 million decreased by Baht 668 million or 31% compared to the previous year. This decrease was primarily due to a shortage of raw materials for suppliers to produce medical device products, which affected the Company's ability to fulfill orders and deliver products to the hospitals. Additionally, in 2022, the situation of the COVID-19 pandemic improved compared to 2021, resulting in a decrease in the demand for medical equipment and devices.

Details of 2022 financial performances were available in Form 56-1 One report 2022 on pages 52-84.

The Chairman of the Meeting: provided all shareholders with opportunities to make inquiries.

**Shareholder Online:** After the COVID-19 pandemic situation is relieved and transitions into the infectious disease under watch, or potentially becomes an endemic or seasonal disease, will there still be a demand for medical tools and equipment in the future?

The Chairman of the Meeting: Currently and over the past two years, both public and private hospitals have prepared themselves to support the treatment of COVID-19, which has now

become an endemic disease. However, in the current situation, hospitals and public health offices still require medical devices for general patients, outpatients, emergency cases, and critical patients. For example, ventilators are still considered necessary for severe and critical patients, which are the standard requirements for medical equipment. However, there is no need for additional medical devices specifically for COVID-19 treatment, as the existing devices are currently sufficient.

**Shareholder Online:** According to the first quarter of 2023, did the company's performance show a trend of improvement?

The Chairman of the Meeting: As mentioned earlier, the requirements for medical devices currently remain in line with the normal standards for the medical device industry. However, due to the severe COVID-19 pandemic in the last 2-3 years, manufacturers have produced a significant amount of medical devices and equipment. This situation has resulted in a shortage of raw materials, particularly chips, impacting production and causing delays in deliveries during the first quarter of 2023.

The Chairman of the Meeting: provided all shareholders with opportunities to make inquiries. It was apparent that there were no inquiries or other opinions.

**Resolution** The Meeting acknowledged the Annual Registration Statement / Annual Report for the year ended 31 December 2022 (Form 56-1 One Report) and the Company's 2022 operating results.

Agenda 3 To consider and approve the statement of financial position and statement of profit or loss and other comprehensive income for the year ended 31 December 2022, audited by certified auditor and Auditor's report.

The Chairman of the Meeting: Assigned Miss Chonticha Pumpreuk to present the details to the meeting.

**Miss Chonticha Pumpruek:** The Company prepared the statement of financial position and statement of profit or loss and other comprehensive income for the year ended December 31, 2022, in Form 56-1 One report, presented as a QR code and submitted to the shareholders along with a notification letter. The financial position and statement of profit or loss and other comprehensive income for the year 2022 were audited by Certified Public Accountants from Grant Thornton Company Limited, who confirmed their accuracy and compliance with the General Accepted Accounting Principles. A summary of the key points is as follows:

# the Statement of Financial Position.

<u>The total assets</u> of the consolidated and separate financial statements have decreased compared to the previous year, due to a decrease in trade receivables and a reduction in the Company's revenue. These effects are a result of the shortage of raw materials from the supplier, which has resulted in the company being unable to deliver products to customers according to their demands, leading to a decrease in the company's sales volume.

<u>The total liabilities</u> of the consolidated and separate financial statements have decreased compared to the previous year by the same percentage of 19%, because the Company has made repayments of loans to financial institutions.

<u>The shareholders' equity:</u> In 2022, the shareholders' equity has increased due to the issuance of the warrants to purchase the newly ordinary shares and the performance of the company in 2022.

<u>Profit and loss statements</u>: In 2022, Total revenues from sales and services was Baht 1,492 million, which decreased by 31% compared to the year 2021. Due to a shortage of raw materials for suppliers to produce medical device products, such as chips, which are essential components for medical equipment production, the Company was unable to deliver products to customers on time and in sufficient quantities according to their orders. The Company is currently in negotiations with suppliers to find solutions for such issues. The Company is also considering to increased the partners to mitigate the risks from the shortage of raw materials. However, the negative impacts from these circumstances will be expected as short-term.

Furthermore, in 2021, the Company had the positive impacts from the COVID-19 pandemic, as there was a high demand for medical devices and equipment. Consequently, the Company met higher revenue in 2021 compared to 2022 when the COVID-19 situation improved. This indicated that the sales volume in 2022 decreased compared to 2021.

Details of the financial statements and operating result of the year 2022 were available in pages 55 through 84 of Form of 56-1 One report.

In terms of net profit, in 2022, the Company and its subsidiaries recorded a net profit of Baht 53 million, which decreased by 93 percent compared to the same period last year. This was due to the recognition of a one-time revenue of Baht 559 million in 2021 from the deconsolidation of subsidiaries' financial statements. This resulted from the sale of the Company's investment in the subsidiary's beauty business.

**The Chairman of the Meeting:** provided all shareholders with opportunities to make inquiries. It was apparent that there were no inquiries or other opinions. Therefore, The Chairman of the Meeting proposed the meeting to consider and casts their votes.

**Resolution** The Meeting passed its resolution to approve the statement of financial position and the statement of profit or loss and other comprehensive income for the year ended 31 December 2022, audited by the Certified auditor and the Auditor's report, with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
Shares	963,901,652	-	-	-
Percentage	100.0000	-	-	-

Agenda 4

To consider and approve the omission of annual dividend payment for the operation of 2022 and the suspension of profit allocation for legal reserve.

The Chairman of the Meeting: The Company has a policy to pay out the dividend not less than 40% of net profit after tax and legal reserve (separate financial statements). However, the separate financial statement of the Company for the year 2022 indicated accumulated loss of Baht 2,109 million. Thus, the Company is unable to pay dividends for the operating result of the year 2021 as outlined in Form 56-1 One Report, which the Company has prepared in QR Code and submitted such information to the shareholders (Enclosure 8). To propose the shareholder meeting to consider and approve the omission of annual dividend payment for the operation of 2022 and the suspension of profit allocation for legal reserve.

**The Chairman of the Meeting:** provided all shareholders with opportunities to make inquiries. It was apparent that there were no inquiries or other opinions. Therefore, The Chairman of the Meeting proposed the meeting to consider and casts their votes.

**Miss Chonticha Pumpruek** (Master of Ceremony) reported that, in this Agenda, the number of shareholders attending the Meeting increased by 1 shareholder, totaling 240,000 shares. Therefore, there were 62 shareholders attending the meeting with total 964,141,652 shares.

# **Resolution** The Meeting passed its resolution to approve with the proposed the omission of annual dividend payment for the operation of 2022 and the suspension of profit allocation for legal reserve, with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
Shares	964,135,652	-	6,000	-
Percentage	100.0000	-	-	-

# Agenda 5

In 5 To consider and approve the re-election of director who will retire by rotation.

**The Chairman of the Meeting:** Before starting the meeting agenda 5, I would like to assign Khun Rujapong Prabhasanobol to be the chairman of the meeting in this agenda and I request permission to leave the meeting room along with Khun Jackrit Lohajaroensub and Khun Pipat Yingseree, as the director who retire by rotation and will be considered to re-election in another term.

The Chairman of the Meeting (Mr. Rujapong Prabhasanobol) Pursuant to Article 18 of the Articles of Association, in every annual general meeting of shareholder, one-third of all Directors shall retire by selecting those who have served longest in office. However, those Directors can be re-elected. This year, 3 Directors shall retire are:

1. Mr. Preecha Nuntnarumit

Director and Chairman of Executive Director.

Director and Executive Director.

3. Mr. Pipat Yingseree

2. Mr. Jackrit Lohajaroensub

Independent Director, Member of the Audit committee, Chairman of Nomination and Remuneration Committees and Member of the Subcommittee on Risk Management. The Board of Directors (excluding 3 of retired directors by rotation) considered and approved with the proposal of the Nomination and Remuneration Committee. The Board of Directors has considered that the 3 persons who shall retire from directorship are those with the knowledge, capability, experience, and expertise which are beneficial to the Company's operation.

In addition, Mr. Pipat Yingseree has the independent qualification under the regulation of SEC and SET and suitable for the director position of the Company by providing the independent opinion with fully qualification of related regulation. The details of the persons nominated as directors appear in Enclosure 2 attached to the invitation letter to submitted shareholders.

The Chairman of the Meeting (Mr. Rujapong Prabhasanobol) provided all shareholders with opportunities to make inquiries. It was apparent that there were no inquiries and other opinions. And to propose the meeting to consider and cast their votes to approve the re-election of three Directors in another term by voting one share per one vote and appointing each individual director as follows:

Firstly, proposed the meeting to consider and reappoint Mr. Preecha Nuntnarumit as Director and Chairman of Executive Director in another term.

Secondly, proposed the meeting to consider and reappoint Mr. Jackrit Lohajaroensb as Director and Executive Director in another term.

Thirdly, proposed the meeting to consider and reappoint Mr. Pipat Yingseree as Independent Director, Member of the Audit committee, Chairman of Nomination and Remuneration Committees and Member of the Subcommittee on Risk Management in another term.

Resolution

the Meeting considered the matter and passed its resolution, as follows:

1. Approved on appointment of Mr. Preecha Nuntnarumit as Director and Chairman of Executive Director, with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
share	939,053,987	287,660	24,800,005	-
percentage	99.9694	0.0306	_	-

2. Approved on appointment Mr. Jackrit Lohajaroensub as Director and Executive Director, with the votes as follows:

	Approval	Disapproval	Disapproval Abstain	
share	926,616,812	287,660	37,237,180	-
percentage	99.9690	0.0310	-	-

3. Approved on appointment Mr. Pipat Yingseree as an Independent Director, Member of the Audit Committee and Chairman of the Nomination and Remuneration Committees and Member of the Subcommittee on Risk Management, with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
share	963,164,993	287,660	688,999	-
percentage	99.9701	0.0299	-	-

Before starting Agenda 6, The Chairman of the Meeting (Mr. Rujapong Prabhasanobol) invited Mr. Preecha Nuntnarumit, Mr. Jackrit Lohajaroensub and Mr. Pipat Yingseree back into the meeting.

**Mr. Preecha Nuntnarumit:** Thank you for re-electing 3 directors in another term. Then back into the Chairman of the Meeting.

# Agenda 6 To consider and approve the Directors' remuneration for the year 2023.

The Chairman of the Meeting: Pursuant to Article 34 of the Articles of Association, the Directors are entitled to receive remuneration from the Company in the form of gratuity, meeting attendance fee, allowance, bonus, or benefits in other forms, which may be fixed or determined by a set of criteria on a case-by-case basis, or to be effective until amended. The Company has authorised the Nomination and Remuneration Committee to propose the remuneration which are determined with the rate comparable to that of the same industry and sufficient to constitute an incentive for quality Directors to remain with the Company. The board of directors considered and proposed the remuneration for the year of 2023 as follows:

Comparison of 2022 and 2023 Director remuneration										
			2022					2023 (Proposed	l year)	
Type Baht/month/ person	Board of Directors	Audit Committee	Risk Management Subcommittee	Executive Committee	Nomination and Remuneration Committee*	Board of Directors	Audit Committee	Risk Management Subcommittee	Executive Committee	Nomination and Remuneration Committee*
Chairman	50,000	30,000	20,000	15,000	20,000	50,000	30,000	20,000	15,000	20,000
Director	28,000	25,000	15,000	10,000	15,000	28,000	25,000	15,000	10,000	15,000
		N	ot exceeding Baht	5,000,000			N	lot exceeding Baht	5,000,000	

\*Nomination and Remuneration Committee and Executive Committee remuneration is considered remuneration for each meeting attendance.

Propose to the 2023 Annual General Meeting of Shareholders to authorise the Board of Directors to consider and allocate the remuneration to other sub-committees within the amount not exceeding Baht 5,000,000.

**The Chairman of the Meeting:** provided all shareholders with opportunities to make inquiries. It was apparent that there were no inquiries or other opinions. Therefore, The Chairman of the Meeting proposed the meeting to consider and casts their votes.

**Resolution** The Meeting passed its resolution to approve the Directors' remuneration for the year 2023 at the amount not exceeding Baht 5,000,000. And authorize the Board of Directors to have authority

to consider and allocate the Directors' remuneration for other sub-committee at the amount not exceeding Baht 5,000,000, with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
shares	964,080,652	61,000	-	-
percentage	99.9937	0.0063	-	-

Agenda 7To consider and approve the appointment of auditor and auditor fees for the year 2023.The Chairman of the Meeting: Pursuant to Section 120 of the Public Limited Companies Act B.E.2535 (1992) (as amended) the Annual General Meeting of Shareholders shall appoint the auditor

and fix the audit fees every year.

In 2023, the Audit Committee had proposed the appointment of auditors for the year 2023 to the Board of Directors for further proposal to the shareholders' meeting. The names of the auditors are as follows:

- 1. Mr. Somckid Tiatragul, CPA No. 2785; or
- 2. Ms. Kanyanat Sriratchatchaval, CPA No. 6549; or
- 3. Ms. Saranya Aharamahaphanit, CPA No. 9919; or
- 4. Ms. Laksamee Deetrakulwattanapol, CPA No. 9056; or
- 5. Ms. Kesanee Srathongphool, CPA No. 9262.

of Grant Thornton Co., Ltd. as the Company's auditors for the fiscal year 2023 and the interim period of 3 quarters. In the event that none of these auditors is available, Grant Thornton shall delegate another representative to review and audit financial statement of the Company. The auditors mentioned above have no relationship and/or interest with the Company, its subsidiaries, executive, major shareholder, or any person related to such persons, and thus is able to conduct an independent audit and offer independent opinion in the Company's Financial Statement.

Therefore, propose to the shareholders' meeting to consider appointing the auditors mentioned above to become the auditor of the Company for the fiscal year 2023. The auditor's fee for the year 2023 is Baht 2,500,000 as same as the fee in 2022 not including non – audit fee (2022: Baht 2,500,000).

	2022	2023	Incr/(decr)
		Proposed year	%
Audited Financial Statements for the year	1,250,000	1,250,000	-
Reviewed Financial Statements for 3 quarters	1,200,000	1,200,000	-
Reviewed Form 56-1 One Report	50,000	50,000	-
Total	2,500,000	2,500,000	-

The Chairman of the Meeting provided all shareholders with opportunities to make inquiries. The chairman of the Meeting proposes the shareholder meeting to consider and casts their votes.

- **Resolution** The Meeting passed its resolution to approve the appointment of the auditors. The names of the auditors are as follows:
  - 1. Mr. Somckid Tiatragul, CPA No. 2785; or
  - 2. Ms. Kanyanat Sriratchatchaval, CPA No. 6549; or
  - 3. Ms. Saranya Aharamahaphanit, CPA No. 9919; or
  - 4. Ms. Laksamee Deetrakulwattanapol, CPA No. 9056; or
  - 5. Ms. Kesanee Srathongphool, CPA No. 9262.

of Grant Thornton Co., Ltd. as the auditor of the Company for the fiscal year 2023 and the interim period of 3 guarters, with the auditor's fee as follows:

Audited Financial Statements for the year Baht 1,250,000 บาท

Reviewed Financial Statements for 3 quarters Baht 1,200,000 บาท

Review 56-1 One-Report Baht 50,000 บาท

Total: Baht 2,500,000 (excluding out-of-pocket expenses), with the votes as follows:

	Approval	Disapproval	Abstain	Voided Ballot(s)
share	964,141,652	-	-	-
percentage	100.0000	-	-	-

# Agenda 8

### To consider and approve other issues (if any)

**The Chairman of the Meeting**: All agendas have been considered and approved from the meeting. If shareholders have any inquires or suggestions, please click in question icon and type the question via Application IR PLUS AGM.

**Shareholder Online:** I would like to follow up for the plan and progress in solving "C" Caution and profit planning of the Company.

**The Chairman of the Meeting:** The Company has a plan and is executing it to address the continuous "C" caution. The details regarding the plan and progress report in resolving the "C" caution for Q1/2023 will be provided during the upcoming meeting scheduled for this month. **Shareholder Online:** Could you please present the strategic plan for this year and following year.

The Chairman of the Meeting: The main business of the Company is in the medical device industry, and the Company also has plans for innovative software related to the medical device business. Furthermore, there are plans to expand the business by increasing the range of products related to medical devices and healthcare, with the aim of achieving significant growth. However, there have been issues where some suppliers are unable to deliver the products on time, which impacts the volume of purchase orders. To address this, the Company has developed a plan to source alternative products and substitutes to mitigate the shortage of raw materials in production. Nevertheless, the Company has never ignored dividend payments and continues to work towards resolving the issue of accumulated losses. These strategic plans are expected to be implemented in the current year and the following year.

Shareholder Online: Can the next meeting be arranged in as on-site meeting?

The Chairman of the Meeting: We will reconsider based on the situation at that time. For this meeting, it will be arranged as an online meeting due to the ongoing considerations regarding the COVID-19 pandemic, particularly after the consecutive holiday period. Therefore, it will be organised as an online meeting.

The Chairman of the Meeting: provided all shareholders with opportunities to make inquiries. It was apparent that there were no inquiries or other opinions.

The Chairman of the Meeting: The Company records video in the meeting today for information to shareholders. If shareholder is interested, he/she is able to access the Company website <u>www.eforl-aim.com</u> and addressed to thanks all shareholders for their devotion of time to attend the Meeting and addressed to close the Meeting.

The Meeting was concluded at 3.33 p.m.

(Signed)

Chairman of the Meeting

Mr. Preecha Nuntnarumit Chairman of the Executive Directors